Log in to search using one of your social media accounts:

 

How Moffitt could play a role in finding a treatment for ovarian cancer
A California biotechnology company has signed an agreement with Moffitt Cancer Center in Tampa to do the research and development work for a potential immunotherapy to treat ovarian cancer. ITUS Corp. (NASDAQ: ITUS), based in San Jose, California, will pay Moffitt about $1.2 million over two years, as part of a cooperative research and development agreement, Amit Kuman, president and CEO of ITUS, said in a conference call Tuesday. Leading the work will be Dr. Jose Conejo Garcia, a M offitt researcher… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 22, 2017 Category: Biotechnology Authors: Margie Manning Source Type: news

Combination immunotherapy targets cancer resistance
Researchers have identified an experimental antibody that overcomes resistance to treatment by targeting a wider range of immune cells linked to tumor growth. (Source: Yale Science and Health News)
Source: Yale Science and Health News - November 21, 2017 Category: Universities & Medical Training Source Type: news

Cure Brain Cancer supports brain cancer immunotherapy trials
(Walter and Eliza Hall Institute) Australian research into new treatments for brain cancer has been boosted by fellowship funding from Cure Brain Cancer Foundation.A three-year fellowship will support Dr Ryan Cross to translate his research into harnessing immune cells to fight brain cancer, a field known as 'cancer immunotherapy'. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 21, 2017 Category: International Medicine & Public Health Source Type: news

The Leukemia & Lymphoma Society awards grant to Savoldo for immunotherapy research
(UNC Lineberger Comprehensive Cancer Center) A grant from The Leukemia& Lymphoma Society will help fund clinical research led by UNC Lineberger's Barbara Savoldo, MD, PhD, into an investigational chimeric antigen receptor (CAR) T-cell treatment for acute lymphoblastic leukemia that would include a built-in 'safety switch.' (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 21, 2017 Category: Cancer & Oncology Source Type: news

New Gene Treatment Effective for Some Leukemia Patients
By genetically altering a patient ’ s T-cells to attack more than one site on cancer cells, researchers hope to devise better treatments. (Source: NYT Health)
Source: NYT Health - November 20, 2017 Category: Consumer Health News Authors: DENISE GRADY Tags: Immunotherapy Leukemia Cancer National Cancer Institute Stanford University University of Pennsylvania June, Carl H Source Type: news

Roche Cancer Drug Rises To Challenge Merck, Bristol-Myers
Tecentriq, a cancer immunotherapy developed by the Swiss drug giant Roche, slowed the progression of previously untreated lung cancer in a large clinical trial when combined with a chemotherapy regimen, the drug giant said. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 20, 2017 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: OTC:RHHBY NYSE:MRK NYSE:BMY NYSE:AZN Source Type: news

Roche announces trial successes in cancer, haemophilia
ZURICH (Reuters) - Roche announced a double dose of trial wins on Monday, saying its immunotherapy Tecentriq mixed with other drugs made advances against lung cancer, while data suggested its haemophilia agent Hemlibra could be used by more patients. (Source: Reuters: Health)
Source: Reuters: Health - November 20, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Immunotherapy biotech BeneVir Biopharm raises $2 million
Gaithersburg-based BeneVir Biopharm Inc. raised has $2 million, according to documents filed this week with the Securities and Exchange Commission. In the Form D, the company said the offering proceeds will be used for working capital, including payment of salaries and bonuses to executive officers. Officials at the company declined to comment further. BeneVir's majority owner, New York City-based HC2 Holdings Inc. (NYSE:HCHC), has been voca l with analysts in recent months about the progress of… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 17, 2017 Category: American Health Authors: Tina Reed Source Type: news

Gut microbiome influences efficacy of PD-1based immunotherapy against epithelial tumors
This piece of research is behind the headline: Gut bacteria " boost " cancer therapy. This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies). The findings are of interest, but don't have any immediate implications for cancer treatment. This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies).The findings are of interest, but don't have any immediate implications for c...
Source: Current Awareness Service for Health (CASH) - November 17, 2017 Category: Consumer Health News Source Type: news

How a poorly explored immune cell may impact cancer immunity and immunotherapy
(Michigan Medicine - University of Michigan) The immune cells that are trained to fight off the body's invaders can become defective. It's what allows cancer to develop. So most research has targeted these co-called effector T-cells. But a new study takes a step back and considers: What if the problem isn't with the effector T-cells but starts higher up the cellular chain? (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 17, 2017 Category: Cancer & Oncology Source Type: news

F.D.A. Speeds Review of Gene Therapies, Vowing to Target Rogue Clinics
The agency plans to speed approval of treatments to get them to the market faster, signaling the quickened pace of advancements in this field. (Source: NYT Health)
Source: NYT Health - November 17, 2017 Category: Consumer Health News Authors: SHEILA KAPLAN and DENISE GRADY Tags: Stem Cells Genetic Engineering Immunotherapy Food and Drug Administration Source Type: news

Seattle Children's opens first pediatric CAR T-Cell trial targeting CD22 and CD19 proteins
(Seattle Children's) Seattle Children's has opened the first chimeric antigen receptor (CAR) T-cell immunotherapy trial in the US for children and young adults with relapsed or refractory CD19- and CD22-positive acute lymphoblastic leukemia (ALL) that will simultaneously attack two targets on cancer cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 16, 2017 Category: International Medicine & Public Health Source Type: news

MMR/MSI Testing in Colorectal Cancer'Alarmingly' Low MMR/MSI Testing in Colorectal Cancer'Alarmingly' Low
Testing for mismatch repair (MMR) deficiency is suboptimal despite endorsement and well-established guidelines. Will that change now that immunotherapy is approved?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 14, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New Techniques to Predict Response to Immunotherapy New Techniques to Predict Response to Immunotherapy
The latest immunotherapy trials suggest that all subgroups benefit, yet not all patients do well. A group of French researchers is tackling this conundrum head-on.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 14, 2017 Category: Consumer Health News Tags: Hematology-Oncology Article Source Type: news

Jax company starts trial on cancer-fighting therapy
Jacksonville-based TapImmune Inc. (Nasdaq: TPIV) has enrolled its final patient in a randomized, Phase 2 clinical study of an immunotherapy that targets breast cancer. TapImmune's therapies help the body's immune system find and fight cancer, which has evolved to hide from and suppress it, CEO Peter Hoang previously told the Business Journal. This approach is outside of the box of traditional treatment methods like surgery, chemotherapy and radiation therapy tha t shut-down pathways for cancer to… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 14, 2017 Category: American Health Authors: Will Robinson Source Type: news

Biotech firms race to recruit good bugs in war on cancer
(Reuters) - Biotech companies are competing to develop medicines using "bugs as drugs" to fight cancer, building on the latest scientific findings that patients with high levels of good gut bacteria are more likely to respond to modern immunotherapy. (Source: Reuters: Health)
Source: Reuters: Health - November 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Special Focus Issue of Immunotherapy explores the use of allergen-specific immunotherapy
(Future Science Group) Immunotherapy, a leading MEDLINE-indexed journal, published by Future Science Group, has released a special focus issue providing insights into the latest advances in allergen immunotherapy covering both environmental and food allergies, with the aim of directing the improvement and optimization of immunotherapy for allergy specific treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 14, 2017 Category: International Medicine & Public Health Source Type: news

Lung Cancer May Grow Faster During Immunotherapy Lung Cancer May Grow Faster During Immunotherapy
A retrospective analysis from France found that 14% of patients with advanced lung cancer showed an acceleration of tumor growth while receiving immunotherapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 13, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Gut Microbiome May Be Key Variable in Immunotherapy Efficacy Gut Microbiome May Be Key Variable in Immunotherapy Efficacy
Could an impaired or unbalanced microbiome account for a patient's failure to respond to immunotherapy?Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2017 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Researchers Build a Cancer Immunotherapy Without Immune Cells
A team has engineered two stem cell lines into 'synthetic T cells' that destroy breast cancer cells in vitro. (Source: The Scientist)
Source: The Scientist - November 13, 2017 Category: Science Tags: Daily News Source Type: news

Cellular network identified that 'short circuits' the antitumor effect of immunotherapies
(The Wistar Institute) Wistar researchers discovered a novel form of crosstalk among tumor cells and other cell types in the tumor microenvironment, elucidating the mechanism of action of an immunotherapeutic strategy that inhibits tumor-associated macrophages (TAMs) and instructing a more effective use of this therapeutic approach. This work was published online in Cancer Cell. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 13, 2017 Category: Cancer & Oncology Source Type: news

Immunotherapy for Metastatic Prostate Cancer Immunotherapy for Metastatic Prostate Cancer
This review explores the promising new role of immunotherapy in the treatment of metastatic castration-resistant prostate cancer.Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 10, 2017 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

Ludwig researchers uncover novel mechanism by which tumors evade cancer immunotherapies
(Ludwig Institute for Cancer Research) A Ludwig Cancer Research study led by Benoit Van den Eynde, Director of Ludwig Brussels, has identified a novel mechanism by which tumors of the aggressive skin cancer melanoma can resist cancer immunotherapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 10, 2017 Category: International Medicine & Public Health Source Type: news

Cancer immunotherapy uses melanin against melanoma
(North Carolina State University) Researchers have developed a melanin-enhanced cancer immunotherapy technique that can also serve as a vaccine, based on early experiments done in a mouse model. The technique is applied via a transdermal patch. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - November 10, 2017 Category: Biology Source Type: news

FDG-PET/CT could improve treatment for NSCLC patients
Using FDG-PET/CT, researchers in Italy have found a correlation between cell-free...Read more on AuntMinnie.comRelated Reading: Study questions value of CT scans after NCSLC surgery PET identifies cell mutations in NSCLC patients ASTRO: Negative PET/CT doesn't always mean dormant NSCLC SNMMI: FDG-PET can monitor immunotherapy for NSCLC (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 9, 2017 Category: Radiology Source Type: news

UCLA helps many to live long and prosper
In Westwood, more than 100 faculty experts from 25 departments have embarked on anall-encompassing push to cut the health and economic impacts of depression in half by the year 2050. The mammoth undertaking will rely on platforms developed by the new Institute for Precision Health, which will harness the power of big data and genomics to move toward individually tailored treatments and health-promotion strategies.On the same 419 acres of land, researchers across the spectrum, from the laboratory bench to the patient bedside, are ushering in a potentially game-changing approach to turning the body ’s immune defenses a...
Source: UCLA Newsroom: Health Sciences - November 9, 2017 Category: Universities & Medical Training Source Type: news

Can scalpel-free surgery help the body kill breast cancer cells?
(University of Virginia Health System) UVA is testing the combined power of focused ultrasound and immunotherapy to enable the body to recognize and destroy metastatic breast cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 8, 2017 Category: International Medicine & Public Health Source Type: news

Mount Sinai scientists create first mathematical model that predicts immunotherapy success
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Researchers at the Icahn School of Medicine at Mount Sinai have created the first mathematical model that can predict how a cancer patient will benefit from certain immunotherapies, according to a study published in Nature. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 8, 2017 Category: Cancer & Oncology Source Type: news

Novel approach could limit common complications of immunotherapy
(University of Chicago Medical Center) Connecting cancer immunotherapy drugs such as anti-CTLA4 and anti-PD-L1 to peptides that bind to tissues in and around tumors enhanced their effects while limiting adverse events. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 8, 2017 Category: Cancer & Oncology Source Type: news

With three products out, Aratana chases its fourth: a canine cancer drug
With its third FDA-approved drug on the market, Aratana Therapeutics is hunting its next product, a canine cancer immunotherapy treatment. The treatment, called AT-014, would be used to treat bone cancer, or osteosarcoma, in dogs. After a tumor is removed, a vaccine is used to prime the dog’s immune system to target any remaining cancer. Aratana (Nasdaq: PETX) expects to obtain conditional licensure for the treatment from the U.S . Department of Agriculture before the end of 2017, which would… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 7, 2017 Category: Pharmaceuticals Authors: Elise Reuter Source Type: news

Pique Therapeutics Announces Positive Results in Phase 2 Clinical Trial of Lead Immunotherapy for Non-Small Cell Lung Cancer
PT 107 showed improvement in overall survival and significant improvement in time to progression, as compared to control In non-squamous patients, the benefit of PT 107 in overall survival was striking and highly significant PT 107 was well tolerated... Biopharmaceuticals, Oncology Pique Therapeutics, cell vaccine, lung cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 7, 2017 Category: Pharmaceuticals Source Type: news

For cancer patients with HIV, immunotherapy appears safe
(Fred Hutchinson Cancer Research Center) A new category of immunotherapies called checkpoint inhibitors that has been highly effective against many different cancers appears safe to use in patients with both advanced malignancies and HIV, a population excluded from earlier trials of such therapies, according to an early-phase trial. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 7, 2017 Category: Cancer & Oncology Source Type: news

URMC Awarded Nearly $6 Million to Study Deadly Bone Infections
The team, in the Center for Musculoskeletal Research, will study how a deadly bacteria gets into bone and how patients ’ immune responses to the bug can actually make them sicker and more likely to die. Armed with this new information, they hope to create new antibiotics and immunotherapies that can defeat the bug. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - November 7, 2017 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

Scientists 'cure' bowel cancer with immunotherapy
Researchers from Memorial Sloan Kettering Cancer Center in New York have developed a new type of radioimmunotherapy. which teaches the body to destroy tumours. (Source: the Mail online | Health)
Source: the Mail online | Health - November 6, 2017 Category: Consumer Health News Source Type: news

ESMO's Practice-Changing Lung Cancer Data: Three Experts Discuss ESMO's Practice-Changing Lung Cancer Data: Three Experts Discuss
At ESMO 2017, Jack West discussed new, potentially practice-changing immunotherapy research with Hossein Borghaei and Sanjay Popat.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 6, 2017 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Ludwig scientists share research at The Society for Immunotherapy of Cancer Annual Meeting
(Ludwig Institute for Cancer Research) Ludwig Cancer Research has released the scope of its participation at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland, Nov. 8-12. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 6, 2017 Category: Cancer & Oncology Source Type: news

$6 million NIH award will advance research on deadly bone infections
(University of Rochester Medical Center) A team at the University of Rochester Medical Center will study how a deadly bacteria gets into bone and how patients' immune responses to the bug can actually make them sicker and more likely to die. Armed with this new information, they hope to create new antibiotics and immunotherapies that can defeat the bug. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 6, 2017 Category: Infectious Diseases Source Type: news

Good Gut Microbes May Help Immunotherapy Drugs Shrink Tumors Good Gut Microbes May Help Immunotherapy Drugs Shrink Tumors
Cancer patients with high levels of good gut bacteria appear more likely to respond to immunotherapy, potentially opening up a new way to optimize the use of modern medicines that are highly effective but only work in some people.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 3, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Immunotherapy for Lung Cancers: First-Line and Beyond Immunotherapy for Lung Cancers: First-Line and Beyond
Drs West, Garon, and Borghaei discuss immunotherapy for selected lung cancers and the potential roles and pitfalls of combination immunotherapy.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 3, 2017 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Cancer treatment response may be affected by gut bacteria
Conclusion This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies). The findings are of interest, but don't have any immediate implications for cancer treatment. We don't know what the conditions that required antibiotic treatment were and whether these could have affected the response to immunotherapy. We don't know whether the antibiotics themselves influenced how well the immunotherapy worked, or whether it was their effect on gut bacteria. We also don't know whether having high levels of part...
Source: NHS News Feed - November 3, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Gut bacteria 'boost' cancer therapy
Trials suggest the trillions of micro-organisms living in us alter immunotherapy's effectiveness. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 3, 2017 Category: Consumer Health News Source Type: news

Good gut microbes may help immunotherapy drugs shrink tumors
LONDON (Reuters) - Cancer patients with high levels of good gut bacteria appear more likely to respond to immunotherapy, potentially opening up a new way to optimize the use of modern medicines that are highly effective but only work in some people. (Source: Reuters: Health)
Source: Reuters: Health - November 2, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Patients' Gut Bugs May Play Role in Cancer Care
Source: HealthDay Related MedlinePlus Pages: Cancer, Cancer Immunotherapy (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - November 2, 2017 Category: Consumer Health News Source Type: news

UK's NICE Gives Roche Drug Green Light for Bladder Cancer UK's NICE Gives Roche Drug Green Light for Bladder Cancer
Britain's healthcare cost-effectiveness agency NICE, which decides if medicines should be used on the state health service, has decided Roche's immunotherapy drug Tecentriq is worth using to treat certain patients with bladder cancer.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 2, 2017 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Bacteria in the gut modulates response to immunotherapy in melanoma
(University of Texas M. D. Anderson Cancer Center) Bacteria that live in the human digestive tract can influence how cancer responds to immunotherapy, opening a new avenue for research to improve treatment, a team led by researchers at The University of Texas MD Anderson Cancer Center reports in the journal Science. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 2, 2017 Category: Cancer & Oncology Source Type: news

Juno touts latest cancer drug results after rivals win FDA approval
Juno Therapeutics Inc. has announced new cancer trial results that could help the drugmaker leapfrog key competitors in the rapidly emerging cancer immunotherapy industry. Juno said the latest data from its lead product candidate, called JCAR017, are stronger than from Novartis Pharmaceuticals Corp. and Kite Pharma Inc. Both rivals recently won Food and Drug Administration approval to start selling their CAR-T (chimeric antigen receptor T cell) treatments. "There's been this odd belief that all… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 2, 2017 Category: American Health Authors: Casey Coombs Source Type: news

Juno touts latest cancer drug results after rivals win FDA approval
Juno Therapeutics Inc. has announced new cancer trial results that could help the drugmaker leapfrog key competitors in the rapidly emerging cancer immunotherapy industry. Juno said the latest data from its lead product candidate, called JCAR017, are stronger than from Novartis Pharmaceuticals Corp. and Kite Pharma Inc. Both rivals recently won Food and Drug Administration approval to start selling their CAR-T (chimeric antigen receptor T cell) treatments. "There's been this odd belief that all… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 2, 2017 Category: Biotechnology Authors: Casey Coombs Source Type: news

Roswell Park Cancer Institute Launches New Gene-Therapy Study Using...
Cancer center begins clinical study open to patients with several cancer types, involving a unique two-pronged immunotherapy strategy(PRWeb November 02, 2017)Read the full story at http://www.prweb.com/releases/2017/11/prweb14874396.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 2, 2017 Category: Pharmaceuticals Source Type: news